Pharsight

Sympazan patents expiration

SYMPAZAN's oppositions filed in EPO
SYMPAZAN IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8765167 OTTER PHARMS Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
Feb, 2024

(3 months ago)

US8603514 OTTER PHARMS Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
Apr, 2024

(2 months ago)

US11541002 OTTER PHARMS Oral film compositions and dosage forms having precise active dissolution profiles
Jan, 2040

(15 years from now)

Sympazan is owned by Otter Pharms.

Sympazan contains Clobazam.

Sympazan has a total of 3 drug patents out of which 2 drug patents have expired.

Expired drug patents of Sympazan are:

  • US8765167
  • US8603514

Sympazan was authorised for market use on 01 November, 2018.

Sympazan is available in film;oral dosage forms.

Sympazan can be used as method of treating seizures.

The generics of Sympazan are possible to be released after 31 January, 2040.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using CLOBAZAM ingredient

Market Authorisation Date: 01 November, 2018

Treatment: Method of treating seizures

Dosage: FILM;ORAL

More Information on Dosage

SYMPAZAN family patents

Family Patents